Takeda’s Maribavir Post-Transplant CMV Indication Should Not Be Limited By Resistance, US Panel Says

 
• By Sue Sutter

Advisory committee unanimously endorses novel antiviral for treatment of post-transplant patients with refractory/resistant cytomegalovirus infection, and in the process rejects US FDA’s proposal to distinguish target population based upon genetic resistance.

Slam dunk
Despite reservations about the pivotal trial, an FDA panel's vote for Takeda's maribavir was a slam dunk. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers